Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.
复制标题
DOI：
10.1080/22221751.2023.2270071
复制
发表时间：
2023-12
影响因子：
13.2
通讯作者：
Ott, Melanie
中科院分区：
文献类型：
--
作者：
Suryawanshi, Rahul K;Taha, Taha Y;McCavitt-Malvido, Maria;Silva, Ines;Khalid, Mir M;Syed, Abdullah M;Chen, Irene P;Saldhi, Prachi;Sreekumar, Bharath;Montano, Mauricio;Foresythe, Kafaya;Tabata, Takako;Kumar, G Renuka;Sotomayor-Gonzalez, Alicia;Servellita, Venice;Gliwa, Amelia;Nguyen, Jenny;Kojima, Noah;Arellanor, Teresa;Bussanich, Aallyah;Hess, Victoria;Shacreaw, Maria;Lopez, Lauren;Brobeck, Matthew;Turner, Fred;Wang, Yuzhu;Ghazarian, Sydney;Davis, Gregg;Rodriguez, Diviana;Doudna, Jennifer;Spraggon, Lee;Chiu, Charles Y;Ott, Melanie
SARS-CoV-2重组体的出现特别令人担忧，因为它们可能导致由于抗原转变而导致的免疫逃避突然增加。最近的重组体XBB和XBB.1.5比以前的重组体如“Deltacron”具有更高的传递性。我们假设，对SARS-CoV-2重组体的免疫力取决于先前对其亲本菌株的暴露。为了检验这一假设，我们检查了通过感染、疫苗接种或突破性感染赋予的Delta或Omicron（BA.1或BA.2）免疫是否可以中和Deltacron和XBB/XBB.1.5重组体。我们发现，Delta、BA.1或BA.2突破性感染对Deltacron及其亲本菌株提供了比疫苗加强剂更好的免疫保护。除了来自BA.2突破组的血清外，没有血清能有效中和XBB谱系或其亲本BA.2.75.2。这些结果支持了我们的假设。反过来，我们的研究结果强调了多价疫苗的重要性，这些疫苗对应于关注的流行变异体的抗原谱，以及变异体特异性诊断，可以指导公共卫生和个人做出应对新出现的SARS-CoV-2重组体的决定。
The emergence of SARS-CoV-2 recombinants is of particular concern as they can result in a sudden increase in immune evasion due to antigenic shift. Recent recombinants XBB and XBB.1.5 have higher transmissibility than previous recombinants such as “Deltacron.” We hypothesized that immunity to a SARS-CoV-2 recombinant depends on prior exposure to its parental strains. To test this hypothesis, we examined whether Delta or Omicron (BA.1 or BA.2) immunity conferred through infection, vaccination, or breakthrough infection could neutralize Deltacron and XBB/XBB.1.5 recombinants. We found that Delta, BA.1, or BA.2 breakthrough infections provided better immune protection against Deltacron and its parental strains than did the vaccine booster. None of the sera were effective at neutralizing the XBB lineage or its parent BA.2.75.2, except for the sera from the BA.2 breakthrough group. These results support our hypothesis. In turn, our findings underscore the importance of multivalent vaccines that correspond to the antigenic profile of circulating variants of concern and of variant-specific diagnostics that may guide public health and individual decisions in response to emerging SARS-CoV-2 recombinants.